Zobrazeno 1 - 10
of 150
pro vyhledávání: '"H. Hausmaninger"'
Autor:
Elisabeth Mueller-Holzner, H. Hausmaninger, K. Estermann, Gudrun Windbichler, A. Pelzer, Christian Marth, Edgar Petru
Publikováno v:
International Journal of Gynecological Cancer. 16:1522-1528
We have previously shown that interferon-gamma 1b (IFN-gamma) in combination with cyclophosphamide and cisplatin significantly prolongs progression-free survival in ovarian cancer. In this phase I/II study, we examined if administration of IFN-gamma
Autor:
P. Willemse, C. Ramazeilles, V. Georgoulias, Veronique Cocquyt, Y. Boudraa, H. Hausmaninger, Robert Paridaens, Christoph C. Zielinski, J. Wildiers, F Van Aelst, N. Azli, H. Samonnig
Publikováno v:
Annals of Oncology, 14(3), 433-440. Oxford University Press
Background: This phase II study evaluated the feasibility and efficacy of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer (MBC).Patients and methods: Women with MBC requiring fi
Autor:
Ernst Kubista, H. Samonigg, Angelika Reiner, Elisabeth Kucera, Michael Gnant, Martina Mittlböck, Michael Seifert, M. Fridrik, Raimund Jakesz, P. Speiser, H. Hausmaninger, L. Szabo, Robert Zeillinger
Publikováno v:
European Journal of Cancer. 35:398-405
The aim of our study was to evaluate if p53 mutations, especially those in the L2/L3 domains of the p53 gene, add prognostic information for node-positive and steroid receptor positive breast cancer patients. Two hundred and five tumour samples from
Autor:
R. Jakesz, H. Samonigg, M. Gnant, E. Kubista, P. Steindorfer, H. Hausmaninger, P. Sevelda, B. Tschurtschenthaler, M. Fridrik, M. Stierer, R. Kolb, G. Steger, null the Austrian Breast Cancer Study Group
Publikováno v:
European Journal of Cancer. 34:66-70
A randomised clinical trial was performed to test whether or not low-dose chemotherapy lasting only 35 days improves the outcome of breast cancer patients with stage I disease and negative oestrogen and progesterone receptors (ER-, PgR-). Between 198
Autor:
S. Oroszy, W. Oberaigner, Erin L. Schenk, C Peschel, K. Aigner, H Huber, F Kummer, C. Prior, H Hausmaninger
Publikováno v:
European Respiratory Journal. 10:392-396
Preliminary studies have shown bioactivity of interferons (IFNs) in the treatment of small-cell lung cancer (SCLC). The aim of the present study was to determine whether, in patients with advanced SCLC, a combination of recombinant IFN-alpha-2c and s
Autor:
M. A. Fridrik, R. Greil, H. Hausmaninger, O. Krieger, P. Oppitz, M. Stöger, J. Klocker, M. Neubauer, W. Helm, J. Pont, B. Fazeny, M. Hudec, I. Simonitsch, T. Radaszkiewicz
Publikováno v:
Annals of Hematology. 93:539-540
Autor:
H. Hausmaninger
Publikováno v:
European Surgery. 23:230-234
Trotz umfangreicher klinischer Untersuchungen konnte in den letzten 20 Jahren die medikamentose Palliativtherapie fortgeschrittener kolorektaler Karzinome nicht entscheidend verbessert werden. Als Standardtherapie galt bisher eine Monotherapie mit 5-
Autor:
H. Hausmaninger
Publikováno v:
European Surgery. 23:70-75
Durch konventionelle Chemotherapieregime konnen bei Patientinnen mit metastasierendem Mammakarzinom in 40 bis 70% der Falle objektive Tumorruckbildungen erreicht werden, allerdings bei nur 10 bis 20% der behandelten Patientinnen in Form einer komplet
Autor:
Heinz Ludwig, P. Oppitz, W. Horvath, M. Fridrik, K. Krauß, Michael Stierer, F. Hofbauer, D. Manfreda, V. Wette, R. Kolb, Ludwig Müller, G. Michlmayr, Michael Schemper, C. C. Zielinski, Ernst Kubista, Lenzhofer R, P. Steindorfer, D. Depisch, Raimund Jakesz, H. Hausmaninger, M. Dünser, H. Samonigg, Ch. Dadak
Publikováno v:
European Surgery. 23:63-69
Autor:
P, Birner, G, Oberhuber, J, Stani, C, Reithofer, H, Samonigg, H, Hausmaninger, E, Kubista, W, Kwasny, D, Kandioler-Eckersberger, M, Gnant, R, Jakesz
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(6)
The purpose of this study was to investigate the prognostic significance of assessment of human epidermal growth factor receptor (HER)-2 oncogene protein overexpression of breast cancer tissue by the United States Food and Drug Administration (FDA)-a